Antitubercular agents: pharmacogenetic factors in the development of adverse effects Medicamentos antituberculosos: influencias farmacogeneticas en el desarrollo de reacciones adversas.
Author
dc.contributor.author
Ligueros,
Author
dc.contributor.author
Saavedra Saavedra, Iván
Author
dc.contributor.author
Neira,
Author
dc.contributor.author
Cruz-Coke,
Author
dc.contributor.author
Saavedra Saavedra, Iván
Author
dc.contributor.author
Kramer,
Author
dc.contributor.author
Gelman,
Author
dc.contributor.author
Nuñez,
Author
dc.contributor.author
Prieto Prieto, Claudia
Admission date
dc.date.accessioned
2019-01-29T14:49:24Z
Available date
dc.date.available
2019-01-29T14:49:24Z
Publication date
dc.date.issued
1990
Cita de ítem
dc.identifier.citation
Revista medica de Chile, Volumen 118, Issue 7, 2018, Pages 727-735
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/160845
Abstract
dc.description.abstract
We studied the distribution of the acetylator phenotype in 47 patients aged 15 to 77 years receiving isonyazid as antituberculous therapy. 62% were fast and 32% slow acetylators. Ethnical, socio-economic and biologic factors were not related to acetylator type. The incidence of liver alterations, mainly elevated transaminase levels, was higher than reported in the literature and was not shown to be influenced by acetylator type. Adverse reactions to isonyacid were not related to drug serum levels.
Antitubercular agents: pharmacogenetic factors in the development of adverse effects Medicamentos antituberculosos: influencias farmacogeneticas en el desarrollo de reacciones adversas.